StreetInsider.com News Articles

Creative Medical Technology expands Project PHOENIX to virtual data collection for veterans

Tue, 16 Jun 2026 09:01:50 -0400

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced it is advancing Project PHOENIX into a nationwide virtual data collection phase targeting U.S. veterans exposed to burn pits and toxic hazards, according to a company press release.

The program, which has received regulatory approval, is designed to enroll an initial cohort of at least 1,000 veterans across the United States. Participants can enroll through a mobile app that captures exposure history, symptom patterns, patient-reported outcomes and longitudinal health data. When biospecimen collection is required, field teams are designed to coordinate locally with veterans to reduce the need for travel to centralized sites.

CELZ

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Tue, 16 Jun 2026 09:00:00 -0400

The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics

Proprietary CELZ-Biodefense Toxic Exposure Atlas™ intended to support AI-driven drug, biologic, biotherapeutic and regenerative therapy discovery

PHOENIX, June 16, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical," "CELZ," or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine, immune modulation and induced pluripotent stem cell ("iPSC") technologies, today announced the next operational milestone in Project PHOENIX, the Company's regulatory-approved, proprietary AI-driven registry and CELZ-Biodefense Regenerative BioDefense Initiative

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Tue, 16 Jun 2026 09:00:00 -0400

The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics

Proprietary CELZ-Biodefense Toxic Exposure Atlas™ intended to support AI-driven drug, biologic, biotherapeutic and regenerative therapy discovery

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Tue, 16 Jun 2026 09:00:00 -0400

The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics

Proprietary CELZ-Biodefense Toxic Exposure Atlas™ intended to support AI-driven drug, biologic, biotherapeutic and regenerative therapy discovery

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Tue, 16 Jun 2026 09:00:00 -0400

The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics

Proprietary CELZ-Biodefense Toxic Exposure Atlas™ intended to support AI-driven drug, biologic, biotherapeutic and regenerative therapy discovery

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Tue, 16 Jun 2026 09:00:00 -0400

The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics

Proprietary CELZ-Biodefense Toxic Exposure Atlas™ intended to support AI-driven drug, biologic, biotherapeutic and regenerative therapy discovery

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Tue, 16 Jun 2026 09:00:00 -0400

The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics

Proprietary CELZ-Biodefense Toxic Exposure Atlas™ intended to support AI-driven drug, biologic, biotherapeutic and regenerative therapy discovery

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Tue, 16 Jun 2026 09:00:00 -0400

The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics

Proprietary CELZ-Biodefense Toxic Exposure Atlas™ intended to support AI-driven drug, biologic, biotherapeutic and regenerative therapy discovery

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Tue, 16 Jun 2026 09:00:00 -0400

The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics

Proprietary CELZ-Biodefense Toxic Exposure Atlas™ intended to support AI-driven drug, biologic, biotherapeutic and regenerative therapy discovery

Form 10-Q CREATIVE MEDICAL TECHNOL For: Mar 31

Fri, 08 May 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260508/26462054.html

Form 10-Q CREATIVE MEDICAL TECHNOL For: Mar 31

Fri, 08 May 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260508/26462054.html

Creative Medical reports 93% response rate in knee osteoarthritis study

Tue, 28 Apr 2026 09:02:02 -0400

Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) reported that 93% of patients in a pilot study of its Ultrasome knee osteoarthritis treatment showed clinically meaningful improvements in mobility and pain reduction. The company said the therapy was well-tolerated with no serious adverse events reported.

Ultrasome is derived from Creative Medical's CELZ-201 cell therapy product, which is currently being evaluated in an FDA-cleared clinical trial called ADAPT. The cell-free format is designed to enable scalable manufacturing, reduced production costs, and off-the-shelf availability compared to traditional cell therapies.

The biotechnology company said osteoarthritis affects over 30 million adults in the United States. Current treatments

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapie